STOCK TITAN

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

ChromaDex Corp. (NASDAQ: CDXC) has rescheduled its third quarter 2024 financial results conference call to Thursday, October 31, 2024, at 4:30 p.m. ET. The company, which specializes in NAD+ research and healthy aging, will release its financial results for the quarter ended September 30, 2024, after market close on the same day. The conference call will include management discussion and a general business update. A replay of the call will be available until November 13, 2024.

ChromaDex Corp. (NASDAQ: CDXC) ha riprogrammato la sua conferenza sulle risultanze finanziarie del terzo trimestre 2024 per giovedì 31 ottobre 2024, alle 16:30 ET. L'azienda, specializzata nella ricerca sul NAD+ e sull'invecchiamento sano, pubblicherà i risultati finanziari per il trimestre conclusosi il 30 settembre 2024, dopo la chiusura del mercato nello stesso giorno. La conferenza includerà una discussione da parte della direzione e un aggiornamento generale sull'attività. Una registrazione della chiamata sarà disponibile fino al 13 novembre 2024.

ChromaDex Corp. (NASDAQ: CDXC) ha reprogramado su llamada de conferencia sobre los resultados financieros del tercer trimestre de 2024 para el jueves 31 de octubre de 2024, a las 4:30 p.m. ET. La empresa, que se especializa en la investigación sobre NAD+ y el envejecimiento saludable, publicará sus resultados financieros para el trimestre finalizado el 30 de septiembre de 2024, después del cierre del mercado el mismo día. La llamada de conferencia incluirá una discusión del equipo directivo y una actualización general del negocio. Se podrá escuchar una repetición de la llamada hasta el 13 de noviembre de 2024.

ChromaDex Corp. (NASDAQ: CDXC)는 2024년 3분기 재무 결과에 대한 컨퍼런스 콜을 2024년 10월 31일 목요일 오후 4시 30분(ET)으로 재조정했습니다. NAD+ 연구 및 건강한 노화 전문 기업인 이 회사는 2024년 9월 30일에 종료된 분기 동안의 재무 결과를 같은 날 시장 종료 후 발표할 것입니다. 이 컨퍼런스 콜에서는 경영진의 논의와 일반 비즈니스 업데이트가 포함될 것입니다. 이 콜의 재생은 2024년 11월 13일까지 이용할 수 있습니다.

ChromaDex Corp. (NASDAQ: CDXC) a reprogrammé sa conférence téléphonique sur les résultats financiers du troisième trimestre 2024 pour le jeudi 31 octobre 2024, à 16h30 ET. L’entreprise, spécialisée dans la recherche sur le NAD+ et le vieillissement sain, publiera ses résultats financiers pour le trimestre clos le 30 septembre 2024, après la fermeture des marchés le même jour. La conférence téléphonique comprendra une discussion avec la direction et une mise à jour générale sur l’activité. Un enregistrement de cet appel sera disponible jusqu’au 13 novembre 2024.

ChromaDex Corp. (NASDAQ: CDXC) hat seinen Konferenzanruf zu den Finanzergebnissen des dritten Quartals 2024 auf Donnerstag, den 31. Oktober 2024, um 16:30 Uhr ET verschoben. Das Unternehmen, das sich auf NAD+-Forschung und gesundes Altern spezialisiert hat, wird am selben Tag nach Marktende seine Finanzergebnisse für das am 30. September 2024 endende Quartal veröffentlichen. Der Konferenzanruf umfasst eine Diskussion des Managements und ein allgemeines Update zum Geschäft. Eine Wiederholung des Anrufs ist bis zum 13. November 2024 verfügbar.

Positive
  • None.
Negative
  • None.

LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it has rescheduled its previously announced conference call to Thursday, October 31, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday, October 31, 2024.

Investor Conference Call:

ChromaDex management will host an investor conference call to discuss the third quarter 2024 results and provide a general business update on Thursday, October 31, 2024, at 4:30 p.m. ET. Participants should call in at least 10 minutes before the call. The dial-in information is as follows:

Date: Thursday, October 31, 2024

Time: 4:30 p.m. ET (1:30 p.m. PT)

Toll-free dial-in number: 1-888-596-4144

Conference ID: 8584242

Webcast link: ChromaDex Third Quarter 2024 Earnings Conference Call

The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.

A replay of the conference call will be available from 7:30 p.m. ET on October 31, 2024, to 11:59 p.m. EDT on Wednesday, November 13, 2024. The replay dial-in information is as follows:

Toll-free replay number: 1-800-770-2030

Replay ID: 8584242#

For additional information on ChromaDex, visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. (NASDAQ: CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

Niagen® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com). ChromaDex supplies pharmaceutical-grade Niagen® to U.S. FDA-registered 503B outsourcing facilities, which compound and distribute intravenous and injectable Niagen® for clinics. These pharmaceutical-grade Niagen® products, known as Niagen IV and Niagen injections, are available exclusively at clinics with a prescription (www.niagenplus.com).

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.

Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

ChromaDex Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310-388-6706 ext. 689

kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:

Ben Shamsian

Lytham Partners

646-829-9701

shamsian@lythampartners.com

Source: ChromaDex Corporation

FAQ

When will ChromaDex (CDXC) report Q3 2024 earnings?

ChromaDex will report its Q3 2024 earnings on Thursday, October 31, 2024, after market close, with a conference call scheduled for 4:30 p.m. ET.

How can investors access ChromaDex (CDXC) Q3 2024 earnings call?

Investors can access the call by dialing 1-888-596-4144 (Conference ID: 8584242) or through the webcast link available on ChromaDex's investor relations website.

Until when will ChromaDex (CDXC) Q3 2024 earnings call replay be available?

The earnings call replay will be available from October 31, 2024, at 7:30 p.m. ET until November 13, 2024, at 11:59 p.m. EDT using the toll-free number 1-800-770-2030 (Replay ID: 8584242#).

ChromaDex Corporation

NASDAQ:CDXC

CDXC Rankings

CDXC Latest News

CDXC Stock Data

574.85M
49.35M
35.39%
23.87%
3.41%
Packaged Foods
Medicinal Chemicals & Botanical Products
Link
United States of America
LOS ANGELES